Market Cap 23.62M
Revenue (ttm) 20.60M
Net Income (ttm) -8.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -41.80%
Debt to Equity Ratio 0.00
Volume 51,500
Avg Vol 55,773
Day's Range N/A - N/A
Shares Out 5.58M
Stochastic %K 7%
Beta 1.05
Analysts Strong Sell
Price Target $33.55

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
DataJim
DataJim Jun. 11 at 8:54 PM
$SCYX Loaded the boat here and with $NGEN I had to sell some $AVUV and $AVDV
0 · Reply
zerodayrounder
zerodayrounder Jun. 10 at 4:37 PM
$GSK doesn't own equity in $SCYX so I consider that a positive for $SPRO -- aligned interests -- clean up royalty structure AND roll SPRO equity into something more fruitful.
0 · Reply
zerodayrounder
zerodayrounder Jun. 10 at 4:33 PM
Let's hope $SPRO doesn't turn into $SCYX (another $GSK license partner) Looks like they are trying to acquire assets. Did a $40 million PIPE in March. Looking for other non-dilutive financing oppy's -- likely probably trying to sell Brexafremme royalties/milestones to GSK! tebi appears to be a bigger drug with higher PYS and more use cases/indications it can pursue. Something's gotta give!!
0 · Reply
DataJim
DataJim Jun. 9 at 5:37 PM
$NGEN @JSP_Dilution_Player - have a look at this one. It was trading around four dollars and then tanked 40% when there was a dilution at 2:50. A lot of smart money in at 2:50 and now it’s trading at 178. Their lead drug showed statistical significant improvement in spinal cord entry phase 2 $SCYX also worth a alert. Cash runway into 2029 smart money in at $7.36 now trading at 4:28.
0 · Reply
pantarei
pantarei Jun. 9 at 1:08 PM
0 · Reply
ViktorSinclair
ViktorSinclair Jun. 9 at 11:53 AM
$SCYX New all-time low after an 8:1 reverse split. tell me why they did a r/s when they were IN compliance?
2 · Reply
Aurum81
Aurum81 Jun. 8 at 7:04 PM
$SCYX add🍀
2 · Reply
pantarei
pantarei Jun. 4 at 10:03 PM
0 · Reply
ViktorSinclair
ViktorSinclair Jun. 4 at 1:38 PM
$SCYX It was pretty dead, then David and co killed it again
0 · Reply
pantarei
pantarei Jun. 4 at 1:14 PM
$SCYX trying
1 · Reply
Latest News on SCYX
Scynexis trading halted, news pending

2026-05-29T23:51:41.000Z - 15 days ago

Scynexis trading halted, news pending


Scynexis announces 1-for-8 reverse stock split

2026-05-22T20:21:28.000Z - 22 days ago

Scynexis announces 1-for-8 reverse stock split


SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026, 4:15 PM EDT - 22 days ago

SCYNEXIS Announces One-for-Eight Reverse Stock Split


SCYNEXIS Transcript: EGM 2026

May 19, 2026, 9:30 AM EDT - 25 days ago

SCYNEXIS Transcript: EGM 2026


Scynexis reports Q1 EPS (42c), consensus (12c)

2026-05-11T23:59:18.000Z - 4 weeks ago

Scynexis reports Q1 EPS (42c), consensus (12c)


SCYNEXIS Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 4 weeks ago

SCYNEXIS Quarterly report: Q1 2026


SCYNEXIS Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 4 weeks ago

SCYNEXIS Earnings release: Q1 2026


Scynexis files to sell 87M shares of common stock for holders

2026-05-01T20:05:19.000Z - 6 weeks ago

Scynexis files to sell 87M shares of common stock for holders


SCYNEXIS Registration statement: Registration filing

May 1, 2026, 8:00 AM EDT - 6 weeks ago

SCYNEXIS Registration statement: Registration filing


SCYNEXIS Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 6 weeks ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 6 weeks ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

SCYNEXIS Proxy statement: Proxy filing


SCYNEXIS Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 2 months ago

SCYNEXIS Transcript: M&A announcement


SCYNEXIS Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 2 months ago

SCYNEXIS Press release: M&A announcement


SCYNEXIS Slides: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 2 months ago

SCYNEXIS Slides: M&A announcement


Poxel announces sale of PXL770 to Scynexis for up to $196M

2026-03-31T11:20:57.000Z - 2 months ago

Poxel announces sale of PXL770 to Scynexis for up to $196M


Scynexis announces $40M private placement

2026-03-31T10:50:10.000Z - 2 months ago

Scynexis announces $40M private placement


SCYNEXIS Announces $40.0 Million Private Placement

Mar 31, 2026, 6:45 AM EDT - 2 months ago

SCYNEXIS Announces $40.0 Million Private Placement


SCYNEXIS Earnings release: Q4 2025

Mar 4, 2026, 7:00 AM EST - 3 months ago

SCYNEXIS Earnings release: Q4 2025


SCYNEXIS Annual report: Q4 2025

Mar 4, 2026, 7:00 AM EST - 3 months ago

SCYNEXIS Annual report: Q4 2025


Cero Therapeutics appoints Eric Francois to board of directors

2026-02-17T13:20:59.000Z - 4 months ago

Cero Therapeutics appoints Eric Francois to board of directors


Scynexis announces presentation highlighting data from SCY-247

2026-01-28T13:25:56.000Z - 4 months ago

Scynexis announces presentation highlighting data from SCY-247


Scynexis completes transfer of BREXAFEMME NDA to GSK

2025-11-19T12:11:19.000Z - 7 months ago

Scynexis completes transfer of BREXAFEMME NDA to GSK

GSK


Scynexis reports Q3 EPS (17c), consensus (20c)

2025-11-05T23:00:31.000Z - 7 months ago

Scynexis reports Q3 EPS (17c), consensus (20c)


SCYNEXIS Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

SCYNEXIS Earnings release: Q3 2025


SCYNEXIS Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

SCYNEXIS Quarterly report: Q3 2025


SCYNEXIS Slides: investor presentation

Nov 5, 2025, 7:00 AM EST - 7 months ago

SCYNEXIS Slides: investor presentation


Scynexis price target lowered to $3 from $4 at Guggenheim

2025-10-28T11:41:34.000Z - 8 months ago

Scynexis price target lowered to $3 from $4 at Guggenheim

GSK


Scynexis announces presentations highlighting data on SCY-247

2025-09-04T12:40:22.000Z - 10 months ago

Scynexis announces presentations highlighting data on SCY-247


SCYNEXIS Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

SCYNEXIS Earnings release: Q2 2025


SCYNEXIS Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

SCYNEXIS Quarterly report: Q2 2025


SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 1 year ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study


SCYNEXIS Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q1 2025


SCYNEXIS Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q1 2025


SCYNEXIS Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Annual report: Q4 2024

Mar 12, 2025, 5:00 PM EDT - 1 year ago

SCYNEXIS Annual report: Q4 2024


SCYNEXIS Earnings release: Q4 2024

Mar 12, 2025, 5:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q4 2024


SCYNEXIS Quarterly report: Q3 2024

Oct 18, 2024, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q3 2024


SCYNEXIS Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Quarterly report: Q2 2024


SCYNEXIS Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q2 2024


SCYNEXIS Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Quarterly report: Q1 2024


SCYNEXIS Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q1 2024


SCYNEXIS Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS Proxy statement: Proxy Filing


SCYNEXIS Earnings release: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q4 2023


SCYNEXIS Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Annual report: Q4 2023


DataJim
DataJim Jun. 11 at 8:54 PM
$SCYX Loaded the boat here and with $NGEN I had to sell some $AVUV and $AVDV
0 · Reply
zerodayrounder
zerodayrounder Jun. 10 at 4:37 PM
$GSK doesn't own equity in $SCYX so I consider that a positive for $SPRO -- aligned interests -- clean up royalty structure AND roll SPRO equity into something more fruitful.
0 · Reply
zerodayrounder
zerodayrounder Jun. 10 at 4:33 PM
Let's hope $SPRO doesn't turn into $SCYX (another $GSK license partner) Looks like they are trying to acquire assets. Did a $40 million PIPE in March. Looking for other non-dilutive financing oppy's -- likely probably trying to sell Brexafremme royalties/milestones to GSK! tebi appears to be a bigger drug with higher PYS and more use cases/indications it can pursue. Something's gotta give!!
0 · Reply
DataJim
DataJim Jun. 9 at 5:37 PM
$NGEN @JSP_Dilution_Player - have a look at this one. It was trading around four dollars and then tanked 40% when there was a dilution at 2:50. A lot of smart money in at 2:50 and now it’s trading at 178. Their lead drug showed statistical significant improvement in spinal cord entry phase 2 $SCYX also worth a alert. Cash runway into 2029 smart money in at $7.36 now trading at 4:28.
0 · Reply
pantarei
pantarei Jun. 9 at 1:08 PM
0 · Reply
ViktorSinclair
ViktorSinclair Jun. 9 at 11:53 AM
$SCYX New all-time low after an 8:1 reverse split. tell me why they did a r/s when they were IN compliance?
2 · Reply
Aurum81
Aurum81 Jun. 8 at 7:04 PM
$SCYX add🍀
2 · Reply
pantarei
pantarei Jun. 4 at 10:03 PM
0 · Reply
ViktorSinclair
ViktorSinclair Jun. 4 at 1:38 PM
$SCYX It was pretty dead, then David and co killed it again
0 · Reply
pantarei
pantarei Jun. 4 at 1:14 PM
$SCYX trying
1 · Reply
pantarei
pantarei Jun. 3 at 7:33 PM
$SCYX this was their plan from the beginning. When you cannnlt succeeded with operations you ise financials tricks to keep bring salaries in the pocket
1 · Reply
ViktorSinclair
ViktorSinclair Jun. 3 at 4:35 PM
$SCYX new all time low… way to go! Does anyone think they care about the shareholders? this is a fucking joke. David must be fired immediately. like today!
0 · Reply
btm811
btm811 Jun. 3 at 3:17 PM
$SCYX yeah so what happens after it eventually goes under a dollar once again?
1 · Reply
XZeroDelta
XZeroDelta Jun. 3 at 2:18 AM
$SCYX the reverse stock split bought us at least 6 to 12 more months. A lot of things can happen between now and then. By that I mean that 2 phase II studies will likely be initiated. I also mean that during that time GSK may have already begun the talks with the FDA about resuming ibrexafungerp manufacturing. It is in both GSK's and Hansoh pharmaceuticals interests to sell the drug because they have already invested in Scynexis by giving milestone payments (in the case of GSK) or upfront cash (in the case of Hansoh). David Angulo has also been buying. I will buy the dip whenever I have some extra cash in the meantime along with the other stocks that I own. Also if a private company also gave Scynexis $40 million in exchange for shares, it's because they believe in Scynexis's potential. The odds of Scynexis becoming profitable are now greater than before so let's see were this takes us. Good luck my fellow longs!
0 · Reply
intheriver
intheriver Jun. 2 at 4:15 PM
$SCYX I haven’t sold yet, but fortunately have good returns in other sectors to offset the loss here. My one hope here is the new investors bring more pressure on management. For starters, I want to see normal press releases announcing earnings dates and earnings calls in advance with a dial-in. Key word here is “normal”. Beyond just compliance, the reverse split should bring a more suitable price level to allow compliance with companies’ investment guidelines. It’s about creating a baseline NORMAL company. I view holding above $5 as an important threshold. I still believe they should have just done a 1 for 10, but chickened out. At some point, the market cap becomes so cheap that the price holds - that’s easier with a 1 for 10. Everything they do brings suspicion, but at least there is a lot more skin in the game with the new issuances. That’s the only hope I have.
2 · Reply
ViktorSinclair
ViktorSinclair Jun. 2 at 12:34 AM
$SCYX They will just keep shorting… hedge funds are taking this guy to the bank. they will own these losers.
1 · Reply
TwongStocks
TwongStocks Jun. 1 at 8:44 PM
Today's reverse split results. 8 NASDAQ stocks with a RS today. Part 2 of 2: $SCYX 1 for 8 Previous close $0.7050, $5.64 split-adjusted Today's high $5.62 Today's close $5.33 🔴Down 5.50% $SMX 1 for 2.285 Previous close $7.00, $15.995 split-adjusted Today's high $17.50 (premarket) Today's close $17.34 🟢Up 8.41% $TBH 1 for 8 Previous close $0.57, $4.56 split-adjusted Today's high $5.22 Today's close $5.01 🟢Up 9.87% $ZOOZ 1 for 20 Previous close $0.3040, $6.08 split-adjusted Today's high $7.00 Today's close $6.08 Closed flat
1 · Reply
LemuelPitkin
LemuelPitkin Jun. 1 at 7:36 PM
$SCYX For those who have yet to listen to the last SCYX shareholder conference discussing SCY-770/future steps. https://www.youtube.com/watch?v=6lFtBB9DogA&t=1s
2 · Reply
ViktorSinclair
ViktorSinclair Jun. 1 at 7:09 PM
$SCYX It’s been nearly three years since they stopped Brexa, and you have to wonder why GSK has never tried to bring it back to market. There’s been no movement in that direction. It doesn’t matter much for SCYX, as they wouldn’t gain much even if it returned, but what was GSK’s plan here? Was it just to fund the development of 247 and secure first rights if it succeeds? Honestly, I think Brexa could do a large percentage of what 247 can, but no one seems willing to try it off-label. And why did they make such a fuss about stopping the Mario trial? In my opinion, they have no intention of ever bringing this to market—but that’s just how I see it. We need David to get all this (and much more) out to the shareholders, but he and IR refuse to talk to any shareholder. At this point I am just waiting for class action suits so I can join on.
1 · Reply
ImadogImaMut
ImadogImaMut Jun. 1 at 5:22 PM
$SCYX I can’t believe my avg is 6.31 is my best try to DCA one I’m convinced is undervalued
1 · Reply
ViktorSinclair
ViktorSinclair Jun. 1 at 4:05 PM
$SCYX David:
1 · Reply
LemuelPitkin
LemuelPitkin Jun. 1 at 3:44 PM
$SCYX 10% down. This week will go to the dumpers. RSS is predictably a period of weakness and disappointment. Myopia on stock price is braindead but its what one should expect from stock speculators. Try to see the bigger picture. Scynexis management can do a lot with regard to the new Scy-770 AMPK agonist. It's potential is as big as Ozempic. Stock price will fall this week yet the science and clinical successes are undeniable and more are on the way as both Scy-770 and Scy-247 will enter Phase II trials this year in order to determine both effectiveness and evaluate for potential side effects. It's a long term project. And do not forget about Brexafemme which still sits in GSK's dungeons. Write and call US Trade Representative asking them to have a talk with GSK about their intentions. Patients no longer have access to Brexafemme. Why is that? If the GSK plan is to release Brexafemme soon, fine. But if not, GSK needs to get an ultimatem. Release the prisoner.
0 · Reply